81 results about "TOFACITINIB CITRATE" patented technology

The invention belongs to the field of medicine and chemical engineering and particularly relates to a preparation method of tofacitinib citrate. The method comprises steps as follows: 1-benzyl-4-methyl-2,6-dihydro-3-piperidone taken as a starting material is subjected to an asymmetric reduction reaction, 1-benzyl-4-methyl-3-piperidone is obtained, and (3R,4R)-cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride is produced under the action of a chiral catalyst; (3R,4R)-cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochlorid and a paratoluensulfonyl chloride protection product 4-chloro-7-(methyl-4-benzenesulfonyl) pyrrolo[2,3-d]pyrimidine of 4-chloropyrrolo[2,3-d]pyrimidine are subjected to a condensation reaction, [(3R,4R)]-1-benzyl-4-methyl-piperidine-3-yl]-methyl-(7H-pyrrolo[2,3-d]pyrimidine-4-yl)-amine is obtained through deprotection, and tofacitinib citrate is obtained through debenzylation protection, an acylation reaction and citric acid salifying. The process route is short, the process cycle is short, chiral synthesis is performed by means of a catalyst, the product purity is improved, the cost is reduced, the yield is high, and the operation is simple and convenient.

The invention discloses a content determining and related substance detection method for tofacitinib citrate. The method is mainly used for determining and examining medicinal raw materials of tofacitinib citrate and related substances by using efficient liquid chromatography. The method disclosed by the invention is high in detection rate of the related substances, high in precision, accurate in content determining result and good in repeatability and recovery rate. The method verified can be used for routine analysis and quality control of raw materials of tofacitinib citrate and a preparation sample.

The invention discloses Tofacitinib citrate tablets composed of Tofacitinib citrate and pharmaceutically acceptable auxiliary materials. The auxiliary materials comprise filler, disintegrating agent, flow aid and coating materials. The filler is microcrystalline cellulose lactose premix with the model of Celactose80, and the weight ratio of the Tofacitinib citrate to the microcrystalline cellulose lactose premix with the model of Celactose80 is 1:5-25. The invention further discloses a preparation method. The Tofacitinib citrate tablets has high content uniformity and have the advantages of being high in dissolving-out speed, stable in chemical property and the like.

The invention provides a preparation method for amorphous tofacitinib citrate. The preparation method is simple, can easily obtain high-purity amorphous tofacitinib citrate, and is suitable for industrial application. The preparation method includes the following steps: under the temperature range between 30 DEG C and 50 DEG C, organic solvent is used for dissolving tofacitinib citrate, so that solution is produced, water which is 15 DEG C to 25 DEG C is added into the solution, so that precipitate is produced, the precipitate is put in the environment of 15 DEG C to 25 DEG C for 4 to 24 hours, and the amorphous tofacitinib citrate is then recovered.

The invention discloses a novel synthetic process of tofacitinib citrate. The novel synthetic process comprises the steps that 1, an initial raw material-1, 10% of palladium on carbon, absolute methanol and ammonium formate are mixed in a reaction container, and reacting is carried out to obtain a midbody-1; 2, the midbody-1 prepared in the step 1 is dissolved into absolute ethyl alcohol, an initial raw material-2 is added, reacting is carried out at the reaction temperature of 20 DEG C to 50 DEG C, reaction liquid is purified to obtain a crude midbody-2 after reacting is finished, and the crude midbody-2 is refined to obtain a refined midbody-2; 3, the refined midbody-2 is subjected to heating reflux and dissolved clarification through absolute ethyl alcohol, a citric acid water solution is dropwise added, and reacting continues to be carried out at the temperature of 50 DEG C to 90 DEG C; then the mixture is slowly cooled to 20 DEG C to 45 DEG C, and stirring and devitrification are carried out; crystals are filtered and washed with ethyl alcohol, drying is carried out under reduced pressure at the temperature of 40 DEG C to 60 DEG C, and white crude tofacitinib citrate is obtained. The chemical synthetic process is more reasonable in route, and the reaction conditions are milder.

The invention relates to a method for preparing tofacitinib citrate. The method comprises the following steps: by taking N-methyl-N-((3R, 4R)-1-benzyl-4-methylpiperidine-3-yl)-7H-pyrrolo (2, 3-d) pyrimidin-4-amine as a raw material, performing hydrogenation to remove an amino protecting group, performing amidation reaction and salt-forming reaction and finally drying to obtain tofacitinib citrate. In the preparation process, after-treatment is not required, the separation of a target intermediate is not required, and only reactants need to be added sequentially. The preparation method of tofacitinib citrate provided by the invention has the advantages of simplicity in operation, high yield, mild conditions and the like, and is suitable for industrial production.

The invention belongs to the field of medicine synthesis and provides a tofacitinib citrate purification method which can effectively remove an impurity G. The method includes adding a tofacitinib citrate crude product to be purified into a mixed solvent, stirring and heating the mixture until the crude product is fully dissolved, cooling the mixture for crystallization, and performing filtrationand vacuum drying to obtain a purified tofacitinib citrate product. The method is simple to operate and suitable for industrial scale-up production, and has obvious impurity removing effects and a high yield.

The invention discloses preparation methods of a tofacitinib citrate intermediate and tofacitinib citrate. The preparation method of the tofacitinib citrate intermediate comprises: preparing N-(1-benzyl-4-methyl-1,2,5,6-tetrahydropiperidine-3-yl)acetamide by using 3-amino-4-methyl-pyridine, acetyl chloride, benzyl chloride and sodium borohydride as raw materials; preparing 1-benzyl-N,4-dimethylpiperidine-3-amine by using the N-(1-benzyl-4-methyl-1,2,5,6-tetrahydropiperidine-3-yl)acetamide, hydrochloric acid, methylamine and sodium borohydride as raw materials; and carrying out resolution and dissociation on the 1-benzyl-N,4-dimethylpiperidine-3-amine, and carrying out salt forming with hydrochloric acid to obtain the product. The invention provides the new tofacitinib citrate intermediatepreparation method, wherein the use amount of the catalytic hydrogenation catalyst is reduced in the preparation process of tofacitinib citrate so as to reduce the cost, and the generation of N-alkylated impurities can be well controlled by adopting the isopropanol/water mixed solvent.

The invention relates to a preparation method of tofacitinib citrate, in particular to high-yield synthesis of tofacitinib citrate. The tofacitinib citrate is synthesized from raw materials including4-chloro-7-pyrrolo[2,3-d]pyrimidine, (BOC)2O, (3R,4R)-(1-benzyl-4-methylpiperidine-3-yl)methylamine-L-di-p-toluoyl tartrate, Pd/C, cyanoacetic acid and citric acid through six steps including an aminoprotection reaction, an amination reaction, a debenzylation reaction, a condensation reaction, a deprotection reaction and a salt forming reaction. The synthesis route provides the preparation methodof tofacitinib citrate, and the preparation method is high in yield, low in cost, easy to operate and suitable for industrialization.

The invention discloses a synthesis method of a tofacitinib citrate starting material N-((3R, 4R)-4-methyl-1-benzyl-3-piperidyl)-N-methyl-7-tolylsulfonyl-7H-pyrrolo[2,3-D]pyrimidine-4-amine(I). The method comprises the specific steps that 4-methylpyridine is adopted as the starting material to be subjected to nucleophilic substitution with benzyl chloride to obtain 4-methyl-1-benzyl-pyridinium chloride, a reduction reaction is performed under the effect of sodium borohydride, a hydroboration-oxidation reaction is performed, hydroxyl oxidation is performed, two chiral centers are introduced in a reductive amination stereoselectivity mode, splitting is performed through cheap chiral acid (L-DTTA) easy to obtain to obtain an optically pure intermediate body (3R, 4R)-(1-benzyl-4-methyl-piperidine-3-yl)-methyl amine, and finally, the intermediate body and 4-chloropyr are condensed to obtain the tofacitinib citrate starting material. The whole method is easy to implement and low in cost, raw materials are easy to obtain, and aftertreatment is easy. The formula is shown in the description.

The invention discloses an N-[(3R,4R)-1-benzyl-4-methylpiperidine-3-yl]-N-methyl-7H-pyrrolo[2,3-d] pyrimidine-4-amine crystal and a preparation method thereof. The method comprises steps as follows: firstly, 4-chloro-7-(p-tolylsulfonyl) pyrrolo [2,3-d] pyrimidine, 1-benzyl-4-methyl-3-aminomethyl dihydrochloride, potassium carbonate and water are added to a reaction vessel sequentially, heated and subjected to thermal insulation, and white solids are obtained; the white solids, sodium hydroxide and n-butyl alcohol are added to the reaction vessel sequentially, an obtained organic phase is washed with water, then anhydrous magnesium sulfate is added to the organic phase for dehydration, and a dichloromethane extracting solution is obtained; finally, eluting and curing are performed, and the crystal is obtained. The purity of the crystal is higher than 99.9%. According to a final product tofacitinib citrate synthesized with the intermediate, related substances are controlled to be lower than 0.1%, and the preparation of the crystal has great technical advantage and research value.

The invention belongs to the field of pharmaceutical preparations, and specifically relates to a tofacitinib citrate sustained release tablet and a preparation method thereof. The sustained release tablet includes tofacitinib citrate, a skeleton material and a filling agent; and the skeleton material includes a corrosive skeleton material and a hydrophilic gel skeleton material. The sustained release tablet is simple in preparation technology, high in process reproducibility and suitable for large-scale industrial production.

The invention relates to a tofacitinib-citrate tablet and a method for preparing the tofacitinib-citrate tablet, and belongs to the technical field of medical preparations. The tofacitinib-citrate tablet provided by the invention is prepared from an active ingredient, an auxiliary material and coating powder, wherein the active ingredient is tofacitinib citrate; the auxiliary material is prepared from the following raw materials in percentage by weight: 57 to 62 percent of microcrystalline cellulose, 30 to 35 percent of lactose, 2.0 to 3.0 percent of croscarmellose sodium, 3.0 to 4.0 percent of compound lubricant and 0.5 to 1.5 percent of glidant; metering is carried out according to that the total mass of the active ingredient and the auxiliary material is 100 percent. According to the tofacitinib-citrate tablet provided by the invention, the raw material formula is changed; the sticking problem is solved. The invention provides a method for preparing the tofacitinib-citrate tablet, which is simple to operate and good in reproducibility, at the same time.

Crystalline particle of tofacitinib citrate, process for the preparation of a crystalline particle of tofacitinib citrate, pharmaceutical composition, substantially pure amorphous form of tofacitinib citrate, process for preparing the substantially pure amorphous form of tofacitinib citrate, and use of the crystalline particle of tofacitinib citrate, and the pharmaceutical composition are provided.

Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises:

• • 1. Condensation between intermediates VII and VIII to give intermediate VI
  • 2. Hydrogenation of intermediate VI to give intermediate V
  • 3. Resolution of intermediate V to give intermediate IV with enantiomeric purity >99%
  • 4. Release of intermediate IV in a basic medium to give intermediate III
  • 5. N-acylation reaction of intermediate III to give II (tofacitinib)
  • 6. Salification of intermediate II to give tofacitinib monocitrate (I)

The invention provides a method for preparing Tofacitinib citrate. The method comprises the steps of hydrochloric acid removal, amidation reaction, salt forming and the like. According to the method,the cost is low, the operation is simple and convenient, and the obtained product is high in purity, so that the method is applicable to industrial large-scale production.

The invention relates to a tofacitinib citrate oral solution, in particular to a tofacitinib citrate oral solution with more stable pharmaceutical properties and a preparation method of the tofacitinib citrate oral solution. The tofacitinib citrate oral solution is prepared from tofacitinib citrate, a pH regulator, a preservative, a flavoring agent and water. The tofacitinib citrate oral solutionhas better stability and is suitable for children and old people with dysphagia.

The invention discloses application of tofacitinib citrate and medicinal composition thereof in preparation of a medicament for treating sjogren's syndrome. The medicinal composition contains the tofacitinib citrate and/or optimal pharmaceutically-acceptable carriers or excipient. According to the medicinal composition, the sjogren's syndrome of mouths and eyes is obviously improved.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a tofacitinib citrate intermediate as well as a preparation method and an application thereof. Whereinthe tofacitinib citrate intermediate is N-methyl-N-((3R, 4R)-4-methylpiperidine-3-yl)-7H-pyrrolo [2, 3-D] pyrimidine-4-amine dihydrochloride monohydrate. The preparation method comprises the followingsteps: adding N-methyl-N-((3R, 4R)-1-benzyl-4-methylpiperidine-3-yl)-N-methyl-7H-pyrrolo [2, 3-d] pyrimidine-4-amine into water and an organic solvent, then adding hydrochloric acid and palladium hydroxide carbon, introducing hydrogen to react, and filtering out the palladium hydroxide carbon; cooling to room temperature, dropwise adding an organic solvent, crystallizing, carrying out suction filtration, and drying to obtain the tofacitinib citrate intermediate. The method greatly improves the utilization rate of raw materials, reduces the production cost, and improves the product quality.

The invention relates to the technical field of drug analysis, in particular to a gas-liquid chromatography detection method of a tofacitinib citrate residual solvent. The method comprises the following steps of: configuring an analysis solution; setting chromatographic conditions; and performing determination on a machine. The method can effectively determine the content of the tofacitinib citrate residual solvent, thereby ensuring the controllable quality of the product.

The invention belongs to the field of analytical chemistry, and particularly relates to a citric acid tofacitinib citrate chiral intermediate and an enantiomer thereof. A chromatographic column taking amylase tri(3,5-dimethyl phenyl carbamate) coated porous silica gel microspheres as a filler is adopted. A mixed solution of n-hexane-isopropanol-methanol-diethylamine- trifluoroacetic acid is used as a mobile phase for isocratic elution, and the solution enters a detector for detection. The citric acid tofacitinib citrate chiral intermediate and the enantiomer thereof can be effectively separated, and the method has the advantages of high sensitivity and separation degree, good repeatability and durability, simplicity in operation, and stable and reliable result. The method has extremely important significance in realizing the citric acid tofacitinib citrate chiral intermediate and tofacitinib citrate quality control.